Results 51 to 60 of about 46,924 (216)
bNAber: database of broadly neutralizing HIV antibodies. [PDF]
The discovery of broadly neutralizing antibodies (bNAbs) has provided an enormous impetus to the HIV vaccine research and to entire immunology. The bNAber database at http://bNAber.org provides open, user-friendly access to detailed data on the rapidly ...
Burton, Dennis R +8 more
core +4 more sources
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. [PDF]
Most studies of HIV latency focus on the peripheral population of resting memory T cells, but the brain also contains a distinct reservoir of HIV-infected cells in microglia, perivascular macrophages, and astrocytes.
Alvarez-Carbonell, David +4 more
core +1 more source
Abstract Membrane fusion between HIV and host cells requires interaction between the N‐terminal and C‐terminal repeat regions (NHR and CHR) of the gp41 envelope subunit. A deep hydrophobic pocket (HP) on the surface of NHR is considered crucial in this interaction.
Daniel Polo‐Megías +9 more
wiley +1 more source
Role of CD4 epitopes outside the gp120-binding site during entry of human immunodeficiency virus type 1 [PDF]
CD4 is the primary receptor for human immunodeficiency virus (HIV). The binding site for the surface glycoprotein of HIV type 1 (HIV-1), gp120, has been mapped to the C'-C" region of domain 1 of CD4. Previously, we have shown that a mutant of rat CD4, in
Simon, J.H.M +7 more
core +1 more source
Novel phenylalanine derivatives were identified as HIV‐1 capsid inhibitors. IC‐2i showed significant anti‐HIV‐1 activity at picomolar concentrations. ABSTRACT The HIV‐1 capsid (CA) is a validated antiviral target that plays critical roles in both the early and late stages of the viral life cycle.
Xujie Zhang +18 more
wiley +1 more source
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.
The binding of protein HIV-1 gp120 to coreceptors CCR5 or CXCR4 is a key step of the HIV-1 entry to the host cell, and is predominantly mediated through the V3 loop fragment of HIV-1 gp120.
Phanourios Tamamis +1 more
doaj +1 more source
Myeloid-derived suppressor cells and the pathogenesis of human immunodeficiency virus infection
There are several mechanisms by which human immunodeficiency virus (HIV) can mediate immune dysfunction and exhaustion during the course of infection.
Mahmoud Mohammad Yaseen +2 more
doaj +1 more source
Beyond the Barrier: Epithelial Cells as Immune Sentinels in the Female Genital Tract
ABSTRACT Epithelial cells (ECs) of the female genital tract (FGT) serve as an essential barrier and the first line of defense against sexually transmitted pathogens. Beyond providing a physical barrier, these cells actively contribute to immune responses through pathogen recognition, cytokine release, and modulation of adaptive immune responses ...
Lauren Jirik +3 more
wiley +1 more source
Membrane vesicles derived from the probiotic Lacticaseibacillus casei BL23 demonstrate antimicrobial properties against Escherichia coli and a potential biological effect in improving the overall survival of C. elegans infected with Pseudomonas aeruginosa. These vesicles stimulated immune responses in primary cells without causing toxicity. Our results
Cecilia L. D'Antoni +11 more
wiley +1 more source

